AbbVie Inc.
Venclexta (venetoclax) and acalabrutinib
previously untreated adult chronic lymphocytic leukemia (CLL)
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on Venclexta (venetoclax) and acalabrutinib for previously untreated adult chronic lymphocytic leukemia (CLL) is expected Date TBD.
Primary source
· SEC 8-K
verified 16h ago
“AbbVie announced the FDA approved a supplemental new drug application (sNDA) for the combination regimen of Venclexta (venetoclax) and acalabrutinib for the treatment of previously untreated adult patients with chronic lymphocytic leukemia ”